Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report) had its target price upped by equities research analysts at UBS Group from $21.00 to $22.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s price target would suggest a potential upside of 21.48% from the stock’s previous close.
Separately, William Blair upgraded Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a report on Tuesday, November 19th.
View Our Latest Research Report on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Stock Up 0.6 %
About Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.
Further Reading
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- What Investors Need to Know to Beat the Market
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What is a Special Dividend?
- What Does the Future Hold for Eli Lilly?
- P/E Ratio Calculation: How to Assess Stocks
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.